Imatinib Mesylate Patent Expiration
Imatinib Mesylate is Used for treating tumors and gastrointestinal stromal tumors (GIST) in patients with CD117 positive unresectable or metastatic disease. It was first introduced by Novartis Pharmaceuticals Corp
Imatinib Mesylate Patents
Given below is the list of patents protecting Imatinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Imkeldi | US11957681 | Liquid dosage forms of Imatinib | Apr 27, 2040 | Shorla Oncology |
| Gleevec |
US6958335 (Pediatric) | Treatment of gastrointestinal stromal tumors |
Jun 19, 2022
(Expired) | Novartis |
| Gleevec | US6958335 | Treatment of gastrointestinal stromal tumors |
Dec 19, 2021
(Expired) | Novartis |
| Gleevec |
US6894051 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov 23, 2019
(Expired) | Novartis |
| Gleevec |
US7544799 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2019
(Expired) | Novartis |
| Gleevec |
USRE43932 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2019
(Expired) | Novartis |
| Gleevec | US6894051 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May 23, 2019
(Expired) | Novartis |
| Gleevec | US7544799 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec | USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec |
USRE43932 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec | USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2018
(Expired) | Novartis |
| Gleevec |
US5521184 (Pediatric) | Pyrimidine derivatives and processes for the preparation thereof |
Jul 04, 2015
(Expired) | Novartis |
| Gleevec | US5521184 | Pyrimidine derivatives and processes for the preparation thereof |
Jan 04, 2015
(Expired) | Novartis |
Imatinib Mesylate's Family Patents
